Venus Remedies' manufacturing unit, located in Baddi, Himachal Pradesh, has been recommended for supplying cephalosporin dry powder to UNICEF This achievement is an endorsement of Venus Remedies' commitment to delivering top-quality pharmaceutical products worldwide Venus Remedies Limited, a leading global pharmaceutical company, has recently secured
As the first pharmaceutical company in India to be honored with the REO certification from CII, Venus Remedies stands at the forefront of responsible and sustainable export practices. The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian
The $4.20-billion pharmaceutical market of the Philippines accounts for a significant market for Venus Remedies from the ASEAN region as the company moves a step closer towards emerging as the top oncology medicine supplier from India in Southeast Asia Venus Remedies’ oncology wing has
The company expects this marketing approval to enable it to rapidly expand its operations not only in Saudi Arabia, the largest pharma market in GCC region, but other GCC and MENA countries as well The marketing authorisation from Saudi Arabia comes as an evident
The company has consolidated its position in ASEAN, South America and Eastern Europe regions Venus Remedies has taken another decisive step towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region with the product registration from
The company has consolidated its position in GCC, ASEAN, Balkan and Caribbean regions with marketing approvals from Oman, Malaysia, Bosnia and Trinidad & Tobago for important chemotherapy drugs With this, the number of marketing approvals for its oncology products across 75 countries has gone
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries Venus Remedies has been the largest exporter of meropenem from India in the last three years Riding on the upcoming
The company expects this approval for Meropenem 500mg, Meropenem 1000mg, Meropenem 2000mg, Oxaliplatin 5mg/ml, Paclitaxil 6mg/ml, Cisplatin 1mg/ml, Imipenem/Cilastatin 500mg/500mg of its Carbapenem & Oncology production facilities in Baddi to pave the way for GMP certifications from European Medicines Agency and other Pharmaceutical Inspection
Marking a major step in the global expansion strategy of Venus Remedies through its oncology products, this marketing authorisation from the largest GCC market will enable Venus Remedies to establish a strong foothold in GCC and MENA regions In a decisive step towards making its
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans Venus Remedies Limited, a leading research-based pharmaceutical company, has achieved another significant milestone by securing a Good Manufacturing Practices (GMP) certification from
